Roth Capital set a $6.00 target price on BioDelivery Sciences International Inc. (NASDAQ:BDSI) in a research report released on Monday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other brokerages also recently issued reports on BDSI. Janney Montgomery Scott raised shares of BioDelivery Sciences International from a neutral rating to a buy rating and boosted their price objective for the company from $2.45 to $4.00 in a research report on Friday, September 23rd. FBR & Co reissued a buy rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 20th. Cantor Fitzgerald reissued a hold rating on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a buy rating to a hold rating in a research report on Wednesday, October 19th. Finally, Piper Jaffray Cos. reissued a sell rating and set a $4.00 price objective on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. BioDelivery Sciences International currently has a consensus rating of Hold and an average price target of $6.43.

BioDelivery Sciences International (NASDAQ:BDSI) traded down 2.94% on Monday, hitting $1.65. 241,054 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $2.13 and a 200-day moving average price of $2.37. BioDelivery Sciences International has a 52-week low of $1.50 and a 52-week high of $6.23. The stock’s market cap is $89.29 million.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.04. BioDelivery Sciences International had a negative net margin of 93.61% and a negative return on equity of 309.49%. The firm had revenue of $3.60 million for the quarter, compared to the consensus estimate of $3.58 million. During the same quarter in the prior year, the company earned ($0.39) earnings per share. The company’s quarterly revenue was up 200.0% compared to the same quarter last year. Analysts predict that BioDelivery Sciences International will post ($1.23) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BioDelivery Sciences International Inc. (BDSI) Given a $6.00 Price Target by Roth Capital Analysts” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be read at http://www.dailypolitical.com/2016/11/29/biodelivery-sciences-international-inc-bdsi-given-a-6-00-price-target-by-roth-capital-analysts.html.

In other BioDelivery Sciences International news, CFO Paolantonio Ernest Robert De sold 14,800 shares of the company’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $2.44, for a total transaction of $36,112.00. Following the transaction, the chief financial officer now owns 14,866 shares in the company, valued at approximately $36,273.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Niraj Vasisht sold 47,000 shares of the company’s stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $2.43, for a total transaction of $114,210.00. Following the transaction, the insider now owns 73,081 shares in the company, valued at approximately $177,586.83. The disclosure for this sale can be found here. Corporate insiders own 9.00% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. KCG Holdings Inc. boosted its position in BioDelivery Sciences International by 235.8% in the third quarter. KCG Holdings Inc. now owns 39,347 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 27,630 shares in the last quarter. NEXT Financial Group Inc boosted its position in shares of BioDelivery Sciences International by 42.4% in the third quarter. NEXT Financial Group Inc now owns 49,850 shares of the specialty pharmaceutical company’s stock valued at $135,000 after buying an additional 14,850 shares during the period. Alpine Partners VI LLC acquired a new position in shares of BioDelivery Sciences International during the second quarter valued at $147,000. Krilogy Financial LLC acquired a new position in shares of BioDelivery Sciences International during the second quarter valued at $164,000. Finally, Bank of New York Mellon Corp boosted its position in shares of BioDelivery Sciences International by 9.9% in the third quarter. Bank of New York Mellon Corp now owns 62,945 shares of the specialty pharmaceutical company’s stock valued at $170,000 after buying an additional 5,677 shares during the period. Institutional investors and hedge funds own 51.28% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.